Cell Receptor Inc. is a small life science company based in Geneva with a subsidiary in Kiel, Germany, a member of Life Science Nord. The company holds patents on its newly developed method for the well-tolerated prevention of cancer metastasis, an urgent unmet need. Metastases cause 90% of cancer deaths. The oncology market needs affordable treatments with a broad spectrum of activity. EU, USA, CA, AU and JP have granted our patents based on insights that will notably transform cancer treatment. Our new findings enable a novel treatment approach for the first time: We are interfering with an upstream, newly recognized universal mechanism that regulates all cell growth. Therefore, our findings apply to most cancer types. We are looking for a viable partnership to develop and expand a disruptive, well-tolerated, trail-blazing method to improve cancer treatment. We are collaborating with a network of German university hospitals, have, in cooperation with clinical oncologists, completed the planning of our Phase II proof-of-concept study and believe our project is eligible for a fast track to FDA and EMA approval. Our inventor, Dr. Hans-Åke Fabricius, is affiliated and cooperating with university departments engaged in basic and clinical research on cell proliferation, including cancer.